Implant Composed of Demineralized Bone and Mesenchymal Stem Cells Genetically Modified with AdBMP2/AdBMP7 for the Regeneration of Bone Fractures in Ovis aries

Table 1

Toxicity studies related to the use of adenoviral vectors.

Analytical parameter	Reference range	Group I		Group II		Group III
		Pre S	Post S	Pre S	Post S	Pre S	Post S
Leukocytes (μL)	4000–12000	5507.5 ± 0.3	11086 ± 0.3	9748.3 ± 0.3	8375 ± 0.2	11251.7 ± 0.5	8758.3 ± 0.3
Hemoglobin (g/dL)	9–15	11.9 ± 0.2	9.72 ± 0.1	10.2 ± 0.2	10.3 ± 0.1	10.7 ± 0.1	10.1 ± 0.1
Platelets (thousands/μL)	220–680	376.2 ± 0.5	832.2 ± 0.3	470.3 ± 0.2	779.3 ± 0.4	684.1 ± 0.4	720.8 ± 0.5
PT (g/dL)	6.0–7.9	6.36 ± 0.1	6.68 ± 0.1	6.1 ± 0.0	7.1 ± 0.1	6.8 ± 0.1	6.8 ± 0.1
Albumin (g/dL)	2.4–3.0	3.46 ± 0.1	2.9 ± 0.1	3.1 ± 0.1	3.1 ± 0.1	3.1 ± 0.1	3.2 ± 0.1
Globulin (g/dL)	3.5–5.7	2.86 ± 0.1	3.76 ± 0.2	3.05 ± 0.1	4.2 ± 0.3	3.7 ± 0.2	3.5 ± 0.2
AST (IU/L)	66–194	146.4 ± 0.4	174.6 ± 0.3	131.5 ± 0.3	140.3 ± 0.6	112.1 ± 0.1	104.3 ± 0.2
ALT (IU/L)	12–37	17.8 ± 0.3	27 ± 0.9	19 ± 0.5	16.7 ± 0.3	15 ± 0.6	16.5 ± 0.4
Total bilirubin (mg/dL)	0.0–1.0	0.108 ± 0.4	0.032 ± 0.4	0.1 ± 0.6	0.04 ± 1.1	0.06 ± 0.6	0.04 ± 0.8
Total bilirubin (mg/dL)	0.0–0.2	0.03 ± 0.2	0.03 ± 0.4	0.1 ± 0.8	0.1 ± 1.2	0.04 ± 1.0	0.1 ± 0.7
Indirect bilirubin (mg/dL)	0.0–1.0	0.076 ± 0.6	0.03 ± 0.4	0.1 ± 0.8	0.1 ± 1.2	0.04 ± 1.0	0.1 ± 0.7
Alkaline phosphatase (IU/L)	68–387	305.8 ± 0.5	134.4 ± 0.2	167.5 ± 0.6	188.5 ± 0.3	198 ± 0.4	211.3 ± 0.3
GGT (IU/L)	36–102	53.8 ± 0.2	51.8 ± 0.1	68.2 ± 0.3	73.7 ± 0.3	49.07 ± 0.2	58.0 ± 0.4

Pre S: presurgery; Post S: postsurgery.